Related Experiment Video
Updated: Sep 21, 2025
Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
Published on: January 7, 2019
Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis
Anees Bahji1, Paxton Bach, Marlon Danilewitz
1From the Department of Psychiatry, University of Calgary, Calgary, AB, Canada (AB, DC, DJD, NEG); British Columbia Centre for Substance Use, Vancouver, BC, Canada (AB, PB); Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada (AB); Department of Medicine, University of British Columbia, Vancouver, BC, Canada (PB); Ontario Shores Centre for Mental Health Sciences, Whitby, ON, Canada (MD); Department of Psychiatry, University of Toronto, Toronto, ON, Canada (MD); Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada (AB, DJD); Department of Community Health Sciences, School of Public Health, Boston University (RS); Department of Medicine, Boston University, Boston, MA (RS); and Clinical Translational Science Institute, Boston University, Boston, MA (RS).
Background:
We aimed to determine medications' comparative efficacy and safety for adults with alcohol use disorders.
Methods:
We searched eleven electronic data sources for randomized clinical trials with at least 4 weeks of treatment reporting on alcohol consumption (total abstinence and reduced heavy drinking), dropouts, and dropouts due to adverse events. We conducted network meta-analyses using random-effects, frequentist models, and calculated summary rate ratios (RRs) with 95% confidence intervals (CIs).
Results:
We included 156 trials (N = 27,334). Nefazodone (RR = 2.11; 95% CI, 1.42-3.13), aripiprazole (RR = 1.97; 95% CI, 1.36-2.88), carbamazepine (RR = 1.85; 95% CI, 1.03-3.32), and nalmefene (RR = 1.17; 95% CI, 1.01-1.35) were associated with the most dropouts. Baclofen (RR = 0.83; 95% CI, 0.70-0.97) and pregabalin (RR = 0.63; 95% CI, 0.43-0.94) caused fewer dropouts than placebo. Nalmefene (RR = 3.26; 95% CI, 2.34-4.55), fluvoxamine (RR = 3.08; 95% CI, 1.59-5.94), and topiramate (RR=2.18; 95% CI, 1.36-3.51) caused more dropouts from adverse events over placebo. Gamma-hydroxy-butyrate (RR = 1.90; 95% CI, 1.03-3.53), baclofen (RR = 1.80; 95% CI, 1.39-2.34), disulfiram (RR = 1.71; 95% CI, 1.39-2.10), gabapentin (RR = 1.66; 95% CI, 1.04-2.67), acamprosate (RR = 1.33; 95% CI, 1.15-1.54), and oral naltrexone (RR = 1.15; 95% CI, 1.01-1.32) improved total abstinence over placebo (Fig. 3C). For reduced heavy drinking, disulfiram (RR = 0.19; 95% CI, 0.10-0.35), baclofen (RR = 0.72; 95% CI, 0.57-0.91), acamprosate (RR = 0.78; 95% CI, 0.70-0.86), and oral naltrexone (RR = 0.81; 95% CI, 0.73-0.90) were efficacious against placebo.
Conclusions:
The current meta-analyses provide evidence that several medications for AUDs are effective and safe and encourage the expanded use of these medications in the clinical setting. Our review found that acamprosate (2-3 g/d), disulfiram (250-500 mg/d), baclofen (30 mg/d), and oral naltrexone (50 mg/d) had the best evidence for improving abstinence and heavy drinking for patients with AUD.
Prospero:
CRD42020208946.
More Related Videos
Related Concept Videos
01:27CNS Depressants: Alcohol and Nicotine
01:15Drug Abuse and Addiction: Pharmacological Phenomena
01:24Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...
01:28Depressants
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...
01:28Drug Therapy
Antianxiety Medications
01:26Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...